← All trials
NCT04893512
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Oct 5, 2021
- Completion date
- Oct 5, 2022
- First posted
- May 19, 2021
- Last posted
- Aug 30, 2021
- Enrollment
- 45
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Syneos HealthLead sponsor
- US Specialty Formulations, LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.